Business & M&A
The latest in business & m&a for medical-aesthetics practice owners.
Business & M&A
Galderma Plants Flag in Miami—Aesthetic Capital Expansion Signals Growth Play
Swiss injectable giant opens Miami operations amid U.S. plastic surgery boom.
Business & M&A
Galderma Joins Swiss Market Index—Valuation Milestone
Galderma's SMI inclusion reflects market confidence and signals institutional investor appetite for aesthetics.
Business & M&A
Galderma Raises Full-Year 2026 Earnings Guidance
Stronger-than-expected H1 performance prompts upward revision of profit outlook.
Business & M&A
Evolus Posts Positive Q2 2026 EPS at $0.02
Neuromodulator manufacturer beats earnings estimates by 157%, signaling margin recovery.
Business & M&A
InMode Takeover Bid Lapses—No Deal Reached
An unsolicited acquisition proposal for InMode has expired without a transaction.
Business & M&A
Evolus Posts Positive Q2 EPS, Beats Estimates
Evolus reported Q2 2026 earnings with positive EPS of $0.02, beating analyst expectations by 157%.
Business & M&A
InMode Takeover Bid Lapses—Stock Faces Pressure Without Deal
An unsolicited acquisition proposal for InMode expired without a deal, leaving the RF microneedling and energy-device maker to execute standalone.
Business & M&A
InMode Takeover Bid Expires—Stock Pressure Mounts
Unsolicited acquisition proposal lapses without deal; market reaction signals investor skepticism.
Business & M&A
Galderma's Launch Spend Paying Off as Margins Widen
Heavy investment in new products and market expansion is now flowing through to earnings.
Business & M&A
EL.En. Medical Segment Drives 9% Revenue Growth
Italian laser manufacturer's medical aesthetics business accelerates, outpacing overall company growth.
Business & M&A
EL.En. Profit Surges 45% on Medical Aesthetics Shift
Italian laser manufacturer reports H1 2026 earnings jump driven by aesthetic device sales; signals market consolidation.
Business & M&A
Olympus Cosmetic Acquires Gallaher Plastic Surgery
Roll-up consolidation continues as Olympus absorbs an established multi-location aesthetic practice.
Business & M&A
Wellington Management Buys $1.25M InMode Stake
Major institutional investor signals confidence in RF microneedling and radiofrequency device maker.
Business & M&A
Lilly Invests in K-Beauty to Counter 'Mounjaro Face'
Pharma giant takes equity stakes and co-development deals with Korean aesthetic brands to address GLP-1 side effects.
Business & M&A
Medytox Boosts Daewoong Damages Claim Tenfold to ₩500 Billion
Korean botulinum toxin makers locked in escalating patent and trade secret litigation over strain technology.
Business & M&A
Medytox Escalates Daewoong Damages Claim to ₩500 Billion
South Korea's toxin patent dispute intensifies as Medytox seeks tenfold increase in damages.
Business & M&A
Evolus Stock Seen Up 77% by Wall Street
Analysts project significant upside for the Jeuveau maker, signaling confidence in neuromodulator competition and market share gains.
Business & M&A
Galderma Expands Asia-Pacific Manufacturing
The Restylane maker commits to expanded production footprint in the region, signaling confidence in regional demand and supply-chain localization.
Business & M&A
AbbVie Files Material Event: Botox/Juvéderm Pricing Shift
Allergan Aesthetics signals a move that will ripple through every injector's margin sheet.
Business & M&A
Allergan Aesthetics Revamps Allē Program
Botox and Juvéderm rebate structure shifts—watch your per-unit economics.
Business & M&A
AbbVie Lifts Forecast as Botox Sales Help Offset Humira Decline
Allergan Aesthetics revenue growth outpaces pharma headwinds in updated guidance.
Business & M&A
Galderma Commits $650M to U.S. Manufacturing—Here's Why
European aesthetics giant doubles down on domestic production to secure supply and margins.
Business & M&A
La Beaute Files for Nasdaq IPO—First Medspa Roll-Up to Go Public
Premium Medical Aesthetics Platform seeks public listing, signaling investor appetite for consolidation plays.
Business & M&A
VIO Med Spa Adds Richardson, McKinney; Eyes Prosper
Dallas-based roll-up expands footprint as former Meta exec leads acquisition push.
Business & M&A
Clinique MIKA Expands Montreal Services and Education Offerings
Canadian medspa adds clinical capacity and practitioner training programs.
Business & M&A
Galderma Opens Miami HQ for U.S., LATAM Push
Swiss aesthetics giant consolidates regional operations in Miami to deepen market penetration across the Americas.
Business & M&A
Evolus Beats EPS Forecast; Stock Rallies 2.22%
Neuromodulator maker posts earnings above expectations, signaling sustained demand for Jeuveau.
Business & M&A
ALEXIS LAUREN Medspa Targets Nashville Expansion
Luxury medspa chain eyes Williamson County market as part of regional growth strategy.
Business & M&A
Wall Street Sees 77% Upside in Evolus Stock
Analysts project significant gains for the Dysport and Estyme maker amid market momentum.
Business & M&A
InMode Consolidates Amid Potential Trading Shift
The RF microneedling and energy-device maker shows technical signals of a new market phase.
Business & M&A
Sisram Medical Posts Solid H1 2026 Results
The Alma Lasers parent company delivers interim earnings amid APAC growth.
Business & M&A
Evolus Q2 Revenue Beats Forecast, Raises 2026 Outlook
Evolus delivered EPS above consensus and raised full-year guidance, signaling sustained momentum in the neuromodulator market.
Business & M&A
Sisram Medical H1 2026: APAC Growth Offsets Margin Pressure
Sisram delivered solid interim results driven by Asia-Pacific strength, though gross margins faced headwinds.
Business & M&A
Galderma Consolidates U.S. and LATAM HQ in Miami
Swiss aesthetics giant centralizes North American operations.
Business & M&A
Allergan Aesthetics Overhauls Loyalty Program
Refreshed Allergan Partner Privileges aims to strengthen injector retention amid biosimilar competition.
Business & M&A
Evolus Expands Estyme to Canada, Australia, New Zealand
Strategic partnership with Symatese accelerates international rollout of Jeuveau competitor.
Business & M&A
Evolus Q2 Revenue Beats Forecast, Raises 2026 Outlook
The injectable platform company posts 21% revenue growth and signals sustained momentum in toxin and filler.
Business & M&A
AbbVie Files Material Event on Allergan Aesthetics
SEC filing signals pricing or rebate changes affecting Botox and Juvéderm margins.
Business & M&A
Evolus Posts Third Straight Profitable Quarter
Q2 revenue up 21%; adjusted EBITDA positive for third consecutive quarter; 2026 outlook raised.
Business & M&A
Allergan Refreshes Partner Privileges Loyalty
Updated rebate and support structure aims to retain practices amid Evolus and Galderma pressure.
Business & M&A
Allergan Adds Quarterly Botox Rebate for Growth
New rebate structure ties incentives to volume milestones—a shift in how the company rewards loyalty.
Business & M&A
Rejuran Maker PharmaResearch Acquires Cosmetic Group
South Korean injectable manufacturer expands portfolio through acquisition.
Business & M&A
Allergan Aesthetics Refreshes APP Loyalty Program
Updated Allergan Partner Privileges aims to strengthen rebate and incentive structure.
Business & M&A
Evolus Posts Break-Even Q2—Path to Sustained Profit Clear
Jeuveau maker hits profitability milestone on $84M revenue, raising full-year guidance and signaling margin expansion ahead.
Business & M&A
Beauty Health Q2 Earnings: Device Demand Steady
Beauty Health reports Q2 results amid ongoing energy-device market strength.
Business & M&A
Establishment Labs Raises 2026 Revenue Guidance
ESTA narrows losses and lifts outlook on Cellfina and body-contouring traction.
Business & M&A
Evolus Tops Q2 Revenue Forecast, Raises 2026 Outlook
Jeuveau momentum accelerates; injectable platform becomes the core growth engine.
Business & M&A
Allergan Aesthetics Overhauls Partner Privileges Loyalty Program
Refreshed rebate and incentive structure aims to compete with Galderma and Evolus for practice loyalty.
Business & M&A
Indonesia Opens First Botulinum Toxin Plant
New manufacturing capacity set for 2028 production; supply chain diversification ahead.
Business & M&A
Galderma Raises 2026 Guidance After Robust H1
RBC upgrades outlook as integrated aesthetics and pharma model accelerates.
Business & M&A
Evolus Posts Third Straight Profitable Quarter
Jeuveau maker hits profitability milestone as revenue growth accelerates and management raises full-year guidance.
Business & M&A
Evolus Q2 Revenue Surges 21%, Adjusted EBITDA Swings Positive
Jeuveau revenue accelerates past forecasts; adjusted EBITDA turns positive as profitability gains traction.
Business & M&A
Perceptive Advisors Takes New Stake in Evolus
Institutional investor Perceptive Advisors acquires position in Jeuveau maker, signaling confidence in profitability trajectory.
Business & M&A
Evolus Q2 Revenue Hits $84.1M, Raises 2026 Guidance
Jeuveau maker posts 21% YoY growth and narrows losses as profitability streak extends.
Business & M&A
Hugel Posts Record H1 Earnings on Toxin Growth
South Korean manufacturer reports strong first-half results driven by botulinum toxin demand.
Business & M&A
AbbVie Files Material Event—Allē Rebate Terms Shifting
Botox and Juvéderm loyalty program changes signal margin pressure across the injector base.
Business & M&A
Evolus Files Material Event—Jeuveau Pricing Escalates
Aggressive Evolus Rewards program targeting medspas signals toxin price wars are live.
Business & M&A
Evolus Posts Third Straight Profitable Quarter, Raises Outlook
Revenue growth accelerates; adjusted EBITDA positive for third consecutive quarter.
Business & M&A
Evolus Files Material Event—Jeuveau Pricing Shift Ahead
Evolus signals a strategic move tied to Jeuveau and its loyalty program, likely reshaping toxin economics for practices.
Business & M&A
Galderma Raises 2026 Guidance After $3.1B H1 Sales
Record first-half performance triggers full-year outlook boost, signaling sustained momentum in aesthetics.
Business & M&A
Steel Partners Escalates InMode Pressure Over Governance
Activist investor cites 'egregious' failures, signals potential proxy fight or bid.
Business & M&A
Berenberg Backs Galderma's Integrated Model After H1 Beat
Analyst revises price target and estimates following strong first-half results.
Business & M&A
RBC Lifts Galderma Outlook Following H1 Beat
Analyst follows suit on revised guidance after record first-half sales.
Business & M&A
AbbVie Files Material Event—Botox/Juvéderm Pricing Shift Ahead
SEC 8-K signals Allergan Aesthetics is making moves on Allē loyalty and rebate structure—expect margin pressure across the board.
Business & M&A
Hugel Aesthetics Launches Direct Sales Force for Letybo, Expands US Footprint
Korean toxin maker builds commercial infrastructure with new K-TOX campaign targeting US market share.
Business & M&A
Galderma Posts $3.1B H1 Sales, Raises 2026 Outlook
French-Swiss aesthetics leader reports record first-half revenue and upgrades full-year guidance.
Business & M&A
Hugel Aesthetics Builds U.S. Direct Sales Force for Letybo and K-TOX Campaign
South Korean toxin maker invests in commercial infrastructure to challenge AbbVie and Galderma in the U.S. market.
Business & M&A
Hugel Aesthetics Builds U.S. Footprint with Direct Sales Force for Letybo and K-TOX Campaign
South Korean manufacturer invests in commercial infrastructure to challenge Allergan and Galderma in the U.S. toxin market.
Business & M&A
Hugel Launches Letybo in India, Expanding Asia-Pacific Footprint
Market entry signals Hugel's strategy to build regional density before major U.S. push.
Business & M&A
Hugel Aesthetics Builds Direct Sales Force for Letybo and K-TOX in U.S. Market
Korean aesthetics player invests in commercial infrastructure to compete head-to-head with AbbVie and Galderma in the U.S. toxin and filler space.
Business & M&A
Galderma Posts Record H1 2026 Sales of $3.1B, Raises Full-Year Guidance
Swiss aesthetics giant delivers 24.6% YoY growth and lifts 2026 outlook on strength across injectables and devices.
Business & M&A
Steel Partners Offers $16.75 Per Share for InMode—Device Consolidation Accelerates
PE-backed buyout bid for RF microneedling and energy-device maker signals continued roll-up activity in the aesthetic-device space.
Business & M&A
Hugel Expands US Footprint With Direct Sales Force for Letybo and New K-TOX Campaign
South Korean manufacturer builds domestic infrastructure to compete in the US toxin market.
Business & M&A
Steel Partners Offers to Acquire InMode at $16.75 Per Share; Board Evaluates Rival Bids
PE firm's cash offer for RF microneedling and energy-device leader triggers competitive auction process.
Business & M&A
InMode Reports Q2 Revenue $95.2–$95.4M — Steady Growth Amid Acquisition Uncertainty
InMode's preliminary Q2 results show continued revenue momentum despite the pending Steel Partners bid.
Business & M&A
Galderma Launches Alastin in Japan, Asia-Pacific Markets
Skincare brand enters region as aesthetics demand accelerates across Asia.
Business & M&A
Steel Partners Bids $16.75 Per Share for InMode — What a Takeover Means for Device Buyers
The PE firm's unsolicited offer values the RF and energy-device maker at roughly $1.1B, triggering shareholder and board review.
Business & M&A
InMode Guides Q2 2026 Revenue to $95.2M–$95.4M, Reiterates $365M–$375M Full-Year Target
InMode's Q2 beat and full-year guidance hold steady despite acquisition uncertainty.
Business & M&A
Court Bid Filed to Pause InMode Takeover Review — Shareholder Litigation Clouds Steel Partners Offer
Legal challenge to InMode's acquisition process introduces execution risk and potential delays to the Steel Partners deal.
Business & M&A
Steel Partners Bids $16.75/Share for InMode — What a Takeout Means for Device Economics
Private-equity firm Steel Partners makes unsolicited $16.75-per-share cash offer for InMode, signaling PE appetite for consolidated RF and energy-device platforms.
Business & M&A
L'Oréal Raises Galderma Stake to 20%, Deepening Strategic Investment
Luxury conglomerate's expanded ownership signals confidence in aesthetic dermatology consolidation.
Business & M&A
InMode Guides Q2 Revenue to $95.2M–$95.4M, Reiterates $365M–$375M FY 2026 Target
Device maker's preliminary results beat expectations amid takeover contest.
Business & M&A
Steel Partners Bids $16.75/Share for InMode — Challenging CEO Buyout
Unsolicited cash offer from major shareholder escalates M&A battle for the RF and energy-device maker.
Business & M&A
Steel Partners Bids $16.75/Share for InMode — What a Hostile Takeover Means for Device Buyers
A major shareholder's unsolicited offer upends the aesthetic-device market's M&A calculus.
Business & M&A
L'Oréal Raises Galderma Stake to 20% — What Luxury-Goods Capital Means for Aesthetic Pricing
The beauty conglomerate deepens its commitment to the aesthetic-injectables and device maker.
Business & M&A
Sisram Medical Restructures DAXXIFY China Deal With Fosun — Supply Chain Shift Signals Market Consolidation
The toxin maker reshuffles its Asia-Pacific distribution as competition intensifies.
Business & M&A
L'Oréal Raises Galderma Stake to 20% — Strategic Beauty-Pharma Convergence Play
Luxury conglomerate deepens investment in aesthetics company; signals confidence in injectables and device market.
Business & M&A
Sisram Medical Restructures DAXXIFY China Deal With Fosun — Botulinum Toxin Strategy Shifts
Aesthetic device company revamps toxin distribution partnership; signals market complexity in China toxin licensing.
Business & M&A
Steel Partners Offers $16.75/Share for InMode — Rival Bid Challenges CEO Buyout
Unsolicited cash offer from major shareholder tops competing proposal; device maker's board faces competing valuations.
Business & M&A
L'Oréal Boosts Galderma Stake to 20% — Strategic Consolidation in Aesthetics
L'Oréal's increased investment signals confidence in Galderma's injectables and skincare portfolio amid competitive pressure.
Business & M&A
Sisram Medical Restructures DAXXIFY China Deal With Fosun Unit — Supply Chain Complexity Deepens
A revamped distribution arrangement for Daxxify in China reflects ongoing supply and regulatory challenges in the world's second-largest aesthetics market.
Business & M&A
Steel Partners Bids $16.75/Share for InMode — What a Contested Takeover Means for Device Buyers
Unsolicited offer challenges CEO-led buyout; device consolidation accelerates.
Business & M&A
AbbVie Allergan Aesthetics Files Material Event — Botox and Juvéderm Pricing or Loyalty Changes Likely
SEC filing signals potential shifts to Allē program or product pricing affecting practice margins.
Business & M&A
Evolus Files Material Event on Jeuveau Loyalty Program — Pricing and Rebate Moves Signal Market Pressure
Evolus Rewards program changes suggest competitive response to AbbVie and Galderma toxin pricing.
Business & M&A
Steel Partners Bids $16.75 Per Share for InMode — Unsolicited Offer Challenges CEO Buyout
Activist investor Steel Partners launches rival cash offer for the RF microneedling and energy-device maker.
Business & M&A
InMode Receives Unsolicited Takeover Offer — Consolidation Pressure Mounts in Device Market
InMode shares rose on an unsolicited acquisition proposal, signaling continued PE and strategic interest in high-margin aesthetic device makers.
Business & M&A
AbbVie Files Material 8-K on Allergan Aesthetics — Pricing or Rebate Shift Likely Ahead
AbbVie disclosed a material event related to Allergan Aesthetics, signaling potential changes to Botox/Juvéderm pricing or Allē loyalty terms.
Business & M&A
L'Oréal Boosts Galderma Stake to 20% — Strategic Bet on Aesthetics and Skincare Convergence
L'Oréal increased its ownership in Galderma, signaling confidence in the dermatology and aesthetics player despite recent regulatory setbacks.
Business & M&A
InMode Receives Unsolicited Takeover Offer — Consolidation Pressure Mounts in Energy-Device Space
PE or strategic buyer circles InMode; device M&A cycle accelerates.
Business & M&A
AbbVie Files Material Event on Allergan Aesthetics — Pricing or Rebate Move Likely Incoming
SEC 8-K signals potential changes to Botox/Juvéderm economics; monitor Allē terms closely.
Business & M&A
InMode Confirms Receipt of Unsolicited Takeover Proposal — Strategic Interest Signals Market Consolidation
The Israeli energy-device maker is exploring a potential acquisition, reflecting ongoing PE and strategic buyer interest in aesthetic-device platforms.
Business & M&A
InMode Receives Unsolicited Buyout Proposal at $16.20 per Share — M&A Signals Consolidation Pressure
CEO-led group bids for InMode; signals continued PE and strategic interest in energy-device consolidation.
Business & M&A
Evolus Files Material Events — Jeuveau Pricing and Evolus Rewards Program Under Strategic Review
SEC filings suggest competitive moves or program restructuring for Evolus' toxin and loyalty platform.
Business & M&A
AbbVie Files Multiple Material Events — Botox/Juvéderm Pricing and Rebate Moves Signal Margin Pressure
SEC 8-K filings from AbbVie suggest material changes to Allergan Aesthetics' pricing or loyalty program structure.
Business & M&A
L'Oréal Increases Stake in Galderma to 20% — Consolidation Pressure Mounts in Aesthetics
Luxury conglomerate deepens investment in filler and toxin competitor, signaling confidence in aesthetic injectables market.
Business & M&A
AbbVie Allergan Aesthetics Files Multiple Material Events — Botox/Juvéderm Pricing or Allē Loyalty Shifts Imminent
Three SEC 8-K filings over four months signal repeated strategic moves affecting toxin and filler economics.
Business & M&A
L'Oréal Boosts Galderma Stake to 20% — Strategic Consolidation in Premium Filler Market
Beauty conglomerate deepens commitment to Galderma, signaling confidence in Restylane and Sculptra franchises amid injectable consolidation.
Business & M&A
Evolus Files Material Event — Jeuveau Pricing or Loyalty Program Shift Likely
SEC 8-K signals strategic move in neuromodulator market; watch Evolus Rewards structure and per-unit economics.
Business & M&A
AbbVie Files Multiple Material Events — Botox/Juvéderm Pricing or Rebate Adjustments Likely
Bellwether filings signal margin pressure and loyalty-program recalibration across the injector base.
Business & M&A
Evolus Files Material Event: Jeuveau Loyalty Program Signals Aggressive Medspa Push
Evolus Rewards program expansion suggests competitive pricing moves in the neuromodulator market targeting independent practices.
Business & M&A
AbbVie Files Multiple Material Events — Botox/Juvéderm Pricing or Rebate Moves Imminent
Three SEC filings in four months signal competitive pressure on Allergan Aesthetics' core injectable margins.
Business & M&A
Allergan Aesthetics Files Multiple Material Events: Pricing and Rebate Moves Signal Margin Pressure
Three SEC filings from AbbVie's Allergan Aesthetics suggest significant pricing or rebate adjustments affecting the Botox/Juvéderm/Allē product line.
Business & M&A
Evolus Files Multiple Material Events — Jeuveau Pricing Strategy Intensifies
Evolus's SEC filings suggest aggressive commercial moves in the neuromodulator market, targeting medspa practices directly.
Business & M&A
AbbVie Files Multiple Material Events — Allergan Aesthetics Pricing and Rebate Moves Signal Margin Pressure Across Injectable Market
Three SEC 8-K filings from AbbVie in four months suggest active repricing or loyalty program adjustments in Botox and Juvéderm portfolios.
Business & M&A
Evolus Files Multiple Material Events — Jeuveau Pricing and Loyalty Program Moves Target Medspa Market Share
Three Evolus SEC filings suggest aggressive repricing or rebate restructuring in Jeuveau and Evolus Rewards to compete for injectable volume.
Business & M&A
AbbVie's Allergan Aesthetics Files Multiple Material Events — Pricing and Rebate Moves Ahead
Three SEC 8-K filings signal strategic shifts in Botox/Juvéderm pricing or Allē loyalty structure; injector margins under pressure.
Business & M&A
Evolus Files Multiple Material Events — Jeuveau Competitive Moves Underway
Evolus's SEC filings suggest strategic shifts in Jeuveau pricing or Evolus Rewards loyalty program; price-war dynamics accelerating.
Business & M&A
AbbVie Files Multiple Material Events — Allergan Aesthetics Pricing or Rebate Moves Likely Ahead
Three SEC 8-K filings from AbbVie signal material changes to Allergan Aesthetics' business; Allē loyalty terms may be in flux.
Business & M&A
Evolus Files Multiple Material Events — Jeuveau Competitive Pricing Strategy in Motion
Evolus has filed three SEC 8-Ks; the company is likely adjusting Jeuveau pricing or Evolus Rewards rebate terms to capture market share from Allergan.
Business & M&A
Medspa Franchise vs Independent Practice: Cost, Control, and Unit Economics
Franchises offer turnkey systems and brand leverage; independents keep margin and autonomy. Here's what the real economics look like.
Business & M&A
Should Your Medspa Have a Membership Program? Models, Metrics, and Revenue Impact
Membership programs convert one-time buyers into predictable recurring revenue—but only if you structure them right. Here's what the math actually shows.
Business & M&A
How to Market a Medspa: High-Converting Channels and Real Unit Economics
The channels that drive patient acquisition, retention, and referral for independent medspas—with the metrics that matter to your P&L.
Business & M&A
How Much Revenue Can One MedSpa Treatment Room Generate?
The math on treatment-room revenue depends on utilization rate, service mix, and pricing—here's how to model your own.
Business & M&A
How Much Does It Cost to Open a Medspa? Real Buildout, Device, and Staffing Numbers
A breakdown of the actual capital required: facility, equipment, licensing, staff, and working capital for a standalone aesthetic practice.
Business & M&A
Boulevard vs Aesthetic Record vs PatientNow: Which Medspa Software Fits Your Practice
Three leading platforms dominate medspa software. Here's how they differ in pricing, features, and which practices they actually serve best.
Business & M&A
What It Takes to Open a Medical Spa: Licensing, Medical Director, Ownership, and Capital Requirements
The regulatory and financial foundation for launching a medspa depends on state law, medical director oversight, and whether you're a clinician or investor.
Business & M&A
How to Price Lip Filler at Your MedSpa: Cost Inputs, Market Rates, and Packaging Strategy
Build a defensible lip filler pricing model by understanding COGS, regional demand, and whether to sell by syringe, unit, or package.
Business & M&A
Medspa Profit Margins: What's Normal by Service Line
Gross margins for injectables, laser, and energy devices vary widely—here's what healthy medspas actually achieve and why.
Business & M&A
Botox Cost Per Unit and Profit Margin: The Real Economics for Medspa Owners
Understand wholesale acquisition costs, retail pricing benchmarks, and how rebate programs affect your bottom line.
Business & M&A
InMode Receives Unsolicited $16.20-Per-Share Acquisition Proposal — Device Consolidation Accelerates
CEO-led group bids for InMode; valuation signals market appetite for RF microneedling and energy-device consolidation.
Business & M&A
Med Spa Valuation and Exit Basics: What Makes a Practice Worth Buying
Whether you ever sell or not, understanding what makes a practice valuable to a buyer is a useful lens — because the things that raise your value are mostly the things that make you well-run.
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.